Artera Announces Collaboration with Tempus to Expand Access to Personalized Prostate Cancer Treatment

Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S.

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they will collaborate to expand access to the ArteraAI Prostate Test. Through the collaboration, Tempus and Artera will work together in an exclusive manner to commercialize Artera’s prostate cancer risk stratification test. Tempus is currently connected to more than 50% of all oncologists practicing in the United States.

“We are looking forward to collaborating with Artera to expand access to Artera’s current prostate cancer test,” said Ezra Cohen, MD, Chief Medical Officer at Tempus. “Management of localized prostate cancer has always been a balance between doing too much and not enough. Now, by combining our efforts, we can empower clinicians and patients with critical insights to allow an informed decision at this crucial point in their treatment journey, ensuring that each patient receives the care that is right for them.”

The ArteraAI Prostate Test is an AI-enabled test that provides predictive and prognostic results for patients with localized prostate cancer. The first of its kind, the test provides actionable insights to empower shared decision-making between the patient and clinician to help personalize treatment plans. Test results can be received in 1-2 days after receiving the patient’s specimen. The test is the first AI risk stratification tool for patients with localized prostate cancer recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, and the only test included for its predictive performance regarding the use of short-term androgen deprivation therapy (ADT). The company will roll out new tests for additional indications in the future.

“Collaborating with Tempus is a powerful validation of the hard work and dedication our team at Artera has put into advancing precision medicine,” said Andre Esteva, CEO and co-founder of Artera. “With Tempus’ unmatched expertise, depth, and broad reach, this collaboration strengthens our shared mission to revolutionize patient care and drive breakthroughs in the field of oncology.”

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.

Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.

Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at artera.ai.